

Efficacy of Alendronate Functionalized Solid Lipid Nanoparticles for Osteoporosis Treatment- Development and Release Kinetics Study

Sandhya Pathak, Satyendra Kumar Tripathi and Archana Pandey

Department of Chemistry

Dr. H. S. Gour Central University, Sagar, MP, India

sandhyapathak935@gmail.com

Abstract: Osteoporosis means "Porous bone" is a disease characterized by progressive bone thinning. The deterioration of bone tissue can lead to bone fragility and fracture, especially of the hip, spine, shoulder and wrist. Osteoporosis is caused generally due the decreasing bone mineral density (BMD). Osteoporosis affects 30-40% women after menopause all around the world. Bisphosphonates are the most commonly prescribed drugs for the treatment of osteoporosis in the US and many other countries including India. Alendronate- sodium (AS) is a widely used anti-osteoporosis drug, exhibits strong inhibitory effect on bone resorption performed by osteoclast cells and acts as a potent, specific inhibitor of osteoclast-mediated bone resorption. AS was the first FDA approved bisphosphonate for treatment of osteoporosis in the US in 1995. The objective of the present study was to develop, optimize, and evaluate Solid Lipid Nanoparticles (SLN) of Alendronate-sodium drug which improve the solubility, dissolution rate and enhance the bioavailability of the drug. AS loaded Solid Lipid Nanoparticles have been developed using Glyceral Monosterate (GMS) as lipid and poloxamer 407 as the emulsifier by Emulsion-Solvent evaporation method. Different process variables i.e. concentration of surfactant, homogenization speed and time have been optimized. Formulated SLNs with GMS showed low particle size and high entrapment efficiency. The SLNs were characterized using Zeta sizer, transmission electron microscopy (TEM) and scanning electron microscopy (SEM). In-vitro drug release study was performed by dialysis bag diffusion method and different mathematical models were applied for the release study.

Keywords: Bisphosphonates, Bone Mineral Density (BMD), Drug release, Osteoporosis, Solid Lipid Nanoparticles (SLNs)

REFERENCES

- [1]. Kawalkar, A.K., A Comprehensive Review on Osteoporosis. Journal of Trauma & Orthopaedics, 2014; 9(4): 3-12.
- [2]. Anna, D., Prevention and treatment of osteoporosis in women: an update. Obstet Gynaecol Reprod Med, 2012; 22: 162-9.
- [3]. Dhaliwala, R., et al. The relationship of Physical performance and Osteoporosis prevention with vitamin D in older African Americans (PODA). Contemporary Clinical Trials, 2018; 65: 39-45
- [4]. Weaver, C.M., et al., Calcium plus vitamin D supplementation and risk of fractures. Osteoporosis Int., 2016; 27(1): 367-376.
- [5]. Mithal, A., Bansal, B., Kyer, C.S., Ebeling, P. The Asia-Pacific regional audit epidemiology, costs, and burden of osteoporosis in India 2013: a report of International Osteoporosis Foundation, Indian J Endocrinol Metab, 2014; 18: 449-454.
- [6]. Kyllönen L, D'Este M, Alini M et al. Local drug delivery for enhancing fracture healing in osteoporotic bone. Acta Biomater 2015;11: 412-34.

- [7]. Rumian et al., Sodium alendronate loaded poly (L-lactide-co-glycolide) microparticles immobilized on ceramic scaffolds for local treatment of bone defects, *Regenerative Biomaterials*, 2020, 293–302.
- [8]. K. Miladi, et al., Enhancement of alendronate encapsulation in chitosan nanoparticles, *Journal of Drug Delivery Science and Technology* (2015),
- [9]. Bohrey, S., Chourasia, V, Pandey, A. Optimization by 2³ Factorial Designs, Characterization and In-Vitro Release Kinetics of Lorazepam Loaded PLGA Nanoparticles. *Polymer Science Series A*, 2016; 58(6): 974-984.
- [10]. Nekkanti, V., Rueda, J., Nanoparticles for improved delivery of poorly soluble drugs. *J Drug*, 2016; 1: 18-27.
- [11]. Soumya, M., Gupta, S., JAIN, R., Mazumder, R. Solubility enhancement of poorly water soluble drug by using nanosuspension technology. *Int J Res Dev Pharm Life Sci*, 2013; 2: 642-9.
- [12]. Beloqui, A., Solinis. M.A., Rodriguez-Gascon, A., Almeida, A.J., Preat, V., Nanostructured lipid carriers: Promising drug delivery systems for future clinics. *Nanomedicine*. 2016; 12(1):143-161.
- [13]. Doktorovova, S., Kovacevic, A.B., Garcia, M.L., Souto, E.B. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation. *Eur J Pharm Biopharm*. 2016; 108: 235-252.
- [14]. Ghasemiyeh, P., and Samani, S.M. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages, *Research in Pharmaceutical Sciences*, August 2018; 13(4): 288-303.
- [15]. Zhang Y., Li Z., Zhang, K., et al. Ethyl oleate-containing nanostructured lipid carriers improve oral bioavailability of trans -ferulic acid as compared with conventional solid lipid nanoparticles. *Int J Pharm*. 2016; 511(1): 57-64.
- [16]. Pandita, D., Kumar, S., Poonia, N., Lather, V. Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol. *Food Res Int*. 2014; 62: 1165-1174.
- [17]. Nunes, S., Madureira, A.R., et al. Solid lipid nanoparticles as oral delivery systems of phenolic compounds: Overcoming pharmacokinetic limitations for nutraceutical applications. *Crit Rev Food Sci Nutr*. 2017; 57(9): 1863-1873.
- [18]. Shegokar, R., K.K. Singh, and R.H. Müller, Production and stability of stavudine solid lipid nanoparticles—from lab to industrial scale. *Int J Pharm*. 2011; 416(2): 461-470.
- [19]. Qi, J., Lu, Y., and Wu, W. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. *Curr Drug Metab*, 2012; 13(4): 418-28.
- [20]. A. BELOQUI, M. A. SOLINIS, et al.: Nanostructured lipid carriers: Promising drug delivery systems for future clinics. *Nanomedicine*, 12(1), 143-161 (2016).
- [21]. Makled, S., Nafee, N., Boraie, N. Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor. *Int J Pharm*. 2017; 517(1-2): 312-321.
- [22]. Sastri, K.T., Radha, G.V., Pidikiti, S., Vajjhala, P. Solid lipid nanoparticles: Preparation techniques, their characterization, and an update on recent studies. *J Appl Pharm Sci*, 2020; 10(06): 126–141.
- [23]. Vandana, B.P., Amit, G.M., Preparation and characterization of solid lipid nanoparticles-based gel for topical delivery. *Pharm Nanotechnol*, 2019; 2000: 293–302.
- [24]. Ghasemiyeh, P. and Mohammadi-Samani, S., Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages, *RPS* 2018; 13(4): 288-303.
- [25]. Weng, J., et al. In Vitro Release Study of the Polymeric Drug Nanoparticles: Development and Validation of a Novel Method. *Pharmaceutics* 2020; 12: 732.
- [26]. Zambito, Y. et al. Is dialysis a reliable method for studying drug release from nanoparticulate systems? A case study. *International Journal of Pharmaceutics* 2012; 434 : 2
- [27]. Ramteke, K.H. Mathematical models of drug dissolution: A review. *sch.Acad.J.Pharm*, 2014; 3(5), 388-396.
- [28]. Pathak, S., Tripathi, S., Shukla, S., and Pandey, A. Nanotechnology: An Emerging Field of Osteoporosis Treatment and Kinetic Models For Drug Release Studies – A Review, *SIPN*, 2020; 40(68): 563-577.

- [29]. Sastri, K.T., Radha, G.V., Pidikiti, S., Vajjhala, P. Solid lipid nanoparticles: Preparation techniques, their characterization, and an update on recent studies. *J Appl Pharm Sci*, 2020; 10(06): 126–141.
- [30]. Vandana, B.P., Amit, G.M., Preparation and characterization of solid lipid nanoparticles-based gel for topical delivery. *Pharm Nanotechnol*, 2019; 2000: 293–302.
- [31]. Cohen-Sela, E., Chorny, M., Koroukhov, N., et al., 2009. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. *J. Controlled Release* 133, 90–95,
- [32]. Weng, J., et al. In Vitro Release Study of the Polymeric Drug Nanoparticles: Development and Validation of a Novel Method. *Pharmaceutics* 2020; 12: 732.
- [33]. Pathak, S., Tripathi, S., Shukla, S., and Pandey, A. Nanotechnology: An Emerging Field of Osteoporosis Treatment and Kinetic Models For Drug Release Studies – A Review, *SIPN*, 2020; 40(68): 563-577.